Profile data is unavailable for this security.
About the company
Shanghai Pharmaceuticals Holding Co Ltd is a China-based company principally engaged in pharmaceutical industry, distribution and retail business. The Company's products include innovative drugs, chemical drugs, traditional Chinese medicines and rare disease drugs. The Company's products are mainly used in the cardiovascular system, digestive tract and metabolism, systemic anti-infection, central nervous system, anti-tumor and immunomodulators, musculoskeletal system and respiratory system. In addition, the Company also provides medical logistics and warehousing services. The Company distributes its products both in the domestic market and to overseas markets.
- Revenue in HKD (TTM)285.61bn
- Net income in HKD4.10bn
- Incorporated1994
- Employees48.16k
- LocationShanghai Pharmaceuticals Holding Co LtdShanghai Pharmaceutical MansionNo.200 Taicang RoadSHANGHAI 200020ChinaCHN
- Phone+86 2 163730908
- Fax+86 2 163289333
- Websitehttps://www.sphchina.com/index/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Resources Pharmaceutical Group Ltd | 264.52bn | 4.17bn | 36.38bn | 72.99k | 8.73 | 0.7322 | 3.08 | 0.1375 | 0.6632 | 0.6632 | 42.10 | 7.91 | 1.06 | 7.06 | 3.84 | 3,624,196.00 | 3.36 | 3.02 | 12.72 | 11.35 | 15.67 | 15.72 | 3.18 | 2.87 | 1.09 | 8.70 | 0.412 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
| Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 82.96bn | 4.43bn | 52.55bn | 28.05k | 12.44 | 1.38 | -- | 0.6335 | 2.52 | 2.52 | 47.25 | 22.68 | 1.01 | 6.70 | 4.70 | 2,739,343.00 | 5.67 | 5.90 | 10.56 | 12.40 | 18.07 | 18.70 | 5.63 | 5.56 | 1.35 | -- | 0.3132 | 30.02 | 6.68 | 12.32 | 2.25 | 3.34 | 27.75 | 12.05 |
| Shanghai Pharmaceuticals Holding Co Ltd | 285.61bn | 4.10bn | 65.32bn | 48.16k | 10.44 | 0.5672 | -- | 0.2287 | 1.11 | 1.11 | 77.37 | 20.45 | 1.25 | 7.10 | 3.38 | 5,930,016.00 | 2.40 | 3.53 | 6.33 | 9.34 | 11.34 | 13.15 | 1.92 | 2.66 | 1.07 | 7.55 | 0.403 | 32.89 | 12.21 | 10.35 | -32.92 | -0.5896 | 8.86 | 0.0098 |
| Sinopharm Group Co Ltd | 644.87bn | 9.79bn | 66.16bn | 115.96k | 6.76 | 0.8206 | 3.15 | 0.1026 | 3.14 | 3.14 | 206.65 | 25.83 | 1.59 | 9.06 | 3.72 | 5,561,181.00 | 4.01 | 4.09 | 16.32 | 17.37 | 8.13 | 8.54 | 2.52 | 2.55 | 1.15 | 6.48 | 0.3801 | 30.02 | 8.05 | 11.61 | 6.19 | 9.18 | -7.26 | 8.10 |
Data as of May 31 2024. Currency figures normalised to Shanghai Pharmaceuticals Holding Co Ltd's reporting currency: Hong Kong Dollar HKD
16.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| LSV Asset Managementas of 19 Sep 2022 | 45.84m | 4.99% |
| The Vanguard Group, Inc.as of 09 May 2024 | 34.38m | 3.74% |
| BlackRock Fund Advisorsas of 03 Apr 2024 | 19.89m | 2.17% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 11.50m | 1.25% |
| BlackRock Advisors (UK) Ltd.as of 03 Apr 2024 | 10.04m | 1.09% |
| Brandes Investment Partners LPas of 23 May 2024 | 5.77m | 0.63% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2022 | 5.73m | 0.62% |
| Swedbank Robur Fonder ABas of 29 Feb 2024 | 5.65m | 0.62% |
| Amundi Asset Management SA (Investment Management)as of 22 May 2024 | 5.33m | 0.58% |
| Apo Asset Management GmbHas of 28 Mar 2024 | 4.64m | 0.50% |
More ▼
Data from 31 Mar 2024 - 22 May 2024Source: FactSet Research Systems Inc.
